Zobrazeno 1 - 10
of 102
pro vyhledávání: '"James Blachly"'
Autor:
Alexander R. Marr, Madeline Halpin, Dominique L. Corbin, Yerdanos Asemelash, Steven Sher, Britten K. Gordon, Ethan C. Whipp, Shaneice Mitchell, Bonnie K. Harrington, Shelley Orwick, Samon Benrashid, Virginia M. Goettl, Vedat Yildiz, Andrew D. Mitchell, Olivia Cahn, Alice S. Mims, Karilyn T. M. Larkin, Meixao Long, James Blachly, Jennifer A. Woyach, Rosa Lapalombella, Nicole R. Grieselhuber
Publikováno v:
Experimental Hematology & Oncology, Vol 13, Iss 1, Pp 1-21 (2024)
Abstract Acute myeloid leukemia (AML) is a highly aggressive hematologic cancer with poor survival across a broad range of molecular subtypes. Development of efficacious and well-tolerable therapies encompassing the range of mutations that can arise
Externí odkaz:
https://doaj.org/article/e0b183ba829743ce9571ebd758015fbb
Autor:
Steven Sher, Ethan Whipp, Janek Walker, Pu Zhang, Larry Beaver, Katie Williams, Shelley Orwick, Janani Ravikrishnan, Brandi Walker, Elizabeth Perry, Charles Gregory, Matthew Purcell, Alexander Pan, Pearlly Yan, Lapo Alinari, Amy J. Johnson, Melanie M. Frigault, Joy M. Greer, Ahmed Hamdy, Raquel Izumi, Xiaokui Mo, Deepa Sampath, Jennifer Woyach, James Blachly, John C. Byrd, Rosa Lapalombella
Publikováno v:
Leukemia. 37:326-338
Chronic lymphocytic leukemia (CLL) is effectively treated with targeted therapies including Bruton tyrosine kinase inhibitors and BCL2 antagonists. When these become ineffective, treatment options are limited. Positive transcription elongation factor
Autor:
Alice S. Mims, Anjali Mishra, Shelley Orwick, James Blachly, Rebecca B. Klisovic, Ramiro Garzon, Alison R. Walker, Steven M. Devine, Katherine J. Walsh, Sumithira Vasu, Susan Whitman, Guido Marcucci, Daniel Jones, Nyla A. Heerema, Gerard Lozanski, Michael A. Caligiuri, Clara D. Bloomfield, John C. Byrd, Richard Piekarz, Michael R. Grever, William Blum
Publikováno v:
Haematologica, Vol 103, Iss 6 (2018)
KMT2A partial tandem duplication occurs in approximately 5–10% of patients with acute myeloid leukemia and is associated with adverse prognosis. KMT2A wild type is epigenetically silenced in KMT2A partial tandem duplication; re-expression can be in
Externí odkaz:
https://doaj.org/article/64600a7ff8504256962fa5545939c604
Autor:
Lynne Abruzzo, Matthew Avenarius, Zachary Abrams, Ling Guo, James Blachly, Cecelia Miller, Nyla Heerema, Kevin Coombes
Publikováno v:
Cancer Genetics. :17
Publikováno v:
International Musician. Jun2024, Vol. 122 Issue 6, p20-20. 1/3p.
Publikováno v:
International Musician. Jun2024, Vol. 122 Issue 6, p20-20. 1/3p.
Autor:
Sumithira Vasu, Nidhi Sharma, Alison Walker, Sarah A. Wall, James Blachly, Gregory Behbehani, Hannah Choe, Aarohi Thakkar, Robin J Nakkula, Ella C Troy, Nicole Szuminski, Marcos De Lima, Lynn ODonnell, Dean Anthony Lee
Publikováno v:
Transplantation and Cellular Therapy. 28:S220
Autor:
Maciej Pietrzak, Gerard Lozanski, Michael Grever, Leslie Andritsos, James Blachly, Kerry Rogers, Michal Seweryn
Publikováno v:
International Journal of Computational Biology and Drug Design. 13:555
Autor:
Alice S, Mims, Anjali, Mishra, Shelley, Orwick, James, Blachly, Rebecca B, Klisovic, Ramiro, Garzon, Alison R, Walker, Steven M, Devine, Katherine J, Walsh, Sumithira, Vasu, Susan, Whitman, Guido, Marcucci, Daniel, Jones, Nyla A, Heerema, Gerard, Lozanski, Michael A, Caligiuri, Clara D, Bloomfield, John C, Byrd, Richard, Piekarz, Michael R, Grever, William, Blum
Publikováno v:
Haematologica
KMT2A partial tandem duplication occurs in approximately 5–10% of patients with acute myeloid leukemia and is associated with adverse prognosis. KMT2A wild type is epigenetically silenced in KMT2A partial tandem duplication; re-expression can be in
Autor:
Joseph, Markowitz, Tapas K, Mal, Chunhua, Yuan, Nicholas B, Courtney, Mitra, Patel, Andrew R, Stiff, James, Blachly, Christopher, Walker, Ann-Kathrin, Eisfeld, Albert, de la Chapelle, William E, Carson
Publikováno v:
Protein science : a publication of the Protein Society. 25(5)
It was recently discovered that the NRAS isoform 5 (20 amino acids) is expressed in melanoma and results in a more aggressive cell phenotype. This novel isoform is responsible for increased phosphorylation of downstream targets such as AKT, MEK, and